A rare genetic mutation linked to Alzheimer’s disease is giving researchers an unusually close look at how the disease develops in the brain. Known as the Flemish mutation, it is inherited within a small number of families and causes Alzheimer’s to develop at a relatively young age. It is also associated with an especially severe buildup of abnormal proteins in and around the brain’s blood vessels.
The mutation affects a gene called amyloid precursor protein (APP), which is involved in producing amyloid-beta, one of the proteins that accumulates in Alzheimer’s disease. In people who carry the Flemish mutation, a single change in the gene alters the resulting amyloid-beta protein. The result is a rare form of Alzheimer’s characterized by unusually large amyloid plaques and extensive deposits around blood vessels in the brain. New research published in Nature Structural & Molecular Biology has now revealed just how unusual those deposits are.
Because the mutation is so rare, researchers have had very little human tissue to study. The new research examined brain tissue from just two people, representing the only two known Flemish families worldwide. Using cryo-electron microscopy, a technique that allows scientists to see biological structures at near-atomic resolution, the researchers were able to examine the abnormal amyloid deposits in extraordinary detail.
What they found provides a new clue about how Alzheimer’s-related amyloid can organize itself in the brain and why some inherited forms of the disease produce such severe damage.
What the Flemish amyloid fold actually tells us
The centerpiece of the August 2026 paper published in Nature Structural & Molecular Biology is a protein shape nobody had ever documented before. Loss of the methyl group at residue 21 gives rise to a distinct arrangement, termed the “Flemish fold,” which differs from all previously characterized amyloid-beta folds and is defined by a unique hydrophobic interior. A methyl group is one of the smallest possible chemical units – essentially a carbon atom with three hydrogen atoms attached – and its absence at one specific location in the amyloid-beta chain is enough to generate an entirely new folding geometry.
The Flemish fold is direct evidence that a single atomic-level change can produce a structurally novel assembly with distinct biological consequences. This missing methyl group generates a fold that no researcher had catalogued before, drawn from brain tissue imaged at near-atomic resolution for the first time.
By exposing a phenylalanine residue, the Flemish fold creates a molecular feature that may explain the vascular accumulation of amyloid-beta and associated cerebral hemorrhage in individuals carrying the mutation. Phenylalanine is an amino acid, and when it is exposed on the surface of a filament rather than buried inside, it can interact with surrounding biological structures in ways that a normally folded protein cannot. Those interactions appear to involve the walls of blood vessels – precisely where the Flemish mutation causes its most severe damage.
Cerebral amyloid angiopathy and Flemish Alzheimer’s: the vascular catastrophe
Cerebral amyloid angiopathy is a cerebrovascular disorder characterized by the accumulation of amyloid-beta in the walls of cerebral blood vessels, and is associated with cognitive decline, cerebral hemorrhage, and other neurological pathologies. The blood vessels lose structural integrity as protein deposits accumulate, making them prone to rupture and recurrent lobar intracerebral hemorrhage.
CAA is the second leading cause of spontaneous intracerebral hemorrhage in people over age 60, after hypertension, and currently has no approved cure or effective disease-modifying treatment. Approximately 70% of Alzheimer’s disease patients exhibit hallmarks of CAA pathology, which means deciphering how amyloid-beta accumulates in vessel walls is one of the most urgent unsolved problems in dementia research. The Flemish fold offers the clearest molecular mechanism for vascular amyloid targeting yet documented in a human brain sample.
The exposed phenylalanine residue may also serve as a structural template that researchers can scan for in sporadic (non-inherited) CAA cases. If something analogous occurs in the far larger population of people who develop CAA without carrying the Flemish mutation, identifying shared structural features could point toward drug targets relevant to many more patients.
Why rare mutations matter for everyone
Familial Alzheimer’s disease is predominantly characterized by autosomal dominant genetic mutations in APP, presenilin 1, and presenilin 2, typically manifesting between 30 and 65 years of age and progressing rapidly. These mutations account for a small fraction of total Alzheimer’s cases, but they have historically delivered outsized scientific returns. The amyloid cascade hypothesis – the foundational framework proposing that amyloid-beta accumulation is the upstream event leading to neurodegeneration – counts APP mutations among its earliest and most direct genetic evidence. Rare mutations in APP were the original evidence that amyloid-beta was a likely driver, not an innocent bystander.
The Flemish mutation continues that tradition. It causes unusually large senile plaque cores alongside pronounced vascular amyloid accumulation – a combination that is paradoxical given earlier in vitro findings showing the Flemish variant actually reduces amyloid aggregation tendency compared to the wild-type protein. In human brain tissue, the Flemish-mutant protein produces some of the most damaging amyloid assemblies ever documented, and cryo-electron microscopy provides the structural resolution needed to begin explaining why.
For people with a parent or sibling with early-onset Alzheimer’s, or who are watching someone navigate overlapping diagnoses of CAA and Alzheimer’s, the practical meaning is concrete: the molecular shape of amyloid-beta proteins is not uniform across all patients, and this non-uniformity is almost certainly clinically relevant. The Flemish fold demonstrates that amyloid-beta aggregates are structurally distinct assemblies, each with potentially different toxicity, biological behavior, and interactions with brain tissue and blood vessels — a distinction that current anti-amyloid therapies do not yet account for.
The structural biology revolution and what it enables
Cryo-electron microscopy works by flash-freezing biological samples and imaging them with electron beams, producing structures at near-atomic resolution. The structures in this study were extracted from postmortem parietal lobe tissue – real human brain material, not engineered laboratory models – which means the Flemish fold is a structure that actually forms in the brain of an Alzheimer’s patient, not a computational prediction or an in vitro artifact.
Drug development depends on accurate structural targets. Therapeutic antibodies and small molecules need to bind to precise surface features on the proteins they are designed to neutralize. An antibody designed against a known amyloid-beta fold may bind poorly, or not at all, to the Flemish fold, because the exposed surface features differ fundamentally. Most current anti-amyloid approaches have focused on reducing amyloid-beta synthesis or increasing clearance of brain amyloid aggregates without distinguishing between fold types. This research suggests that distinction will matter for therapeutic precision, particularly as the field moves toward personalized treatment strategies.
Read More: Common supplement may help reduce Alzheimer’s risk
What this means for you
Alzheimer’s disease remains without a cure, and approved therapies such as lecanemab and donanemab clear amyloid-beta from the brain with only modest effects on disease progression. One increasingly supported explanation for their limited benefit is that amyloid-beta is not a single entity but a collection of structurally distinct assemblies, each with potentially different toxicity, biological behavior, and interactions with brain tissue and blood vessels. The Flemish fold is the clearest demonstration yet that this structural diversity is real and consequential.
If you have a family history of early-onset Alzheimer’s or dementia accompanied by stroke-like episodes, speaking to a neurologist about genetic testing is worth considering. CAA often presents as spontaneous lobar intracerebral hemorrhage – which carries a high risk of recurrence – along with transient focal neurologic episodes and progressive cognitive decline. These symptoms can be mistaken for other conditions, and an accurate diagnosis changes clinical management. The structural biology revealed by the Flemish mutation is a meaningful advance for the entire field, and eventually for patients well beyond those two families.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.